SG11202012343TA - Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration - Google Patents

Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Info

Publication number
SG11202012343TA
SG11202012343TA SG11202012343TA SG11202012343TA SG11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA SG 11202012343T A SG11202012343T A SG 11202012343TA
Authority
SG
Singapore
Prior art keywords
onset
progression
age
compositions
treating
Prior art date
Application number
SG11202012343TA
Other languages
English (en)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of SG11202012343TA publication Critical patent/SG11202012343TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11202012343TA 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration SG11202012343TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
PCT/US2019/036946 WO2019241503A1 (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Publications (1)

Publication Number Publication Date
SG11202012343TA true SG11202012343TA (en) 2021-01-28

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202012343TA SG11202012343TA (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Country Status (11)

Country Link
US (2) US20190381071A1 (https=)
EP (1) EP3806862A4 (https=)
JP (1) JP2021527090A (https=)
KR (1) KR20210009422A (https=)
CN (1) CN112566641A (https=)
AU (1) AU2019285065A1 (https=)
BR (1) BR112020025296A2 (https=)
CA (1) CA3103463A1 (https=)
MX (1) MX2020013614A (https=)
SG (1) SG11202012343TA (https=)
WO (1) WO2019241503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) * 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
WO2022244929A1 (ko) * 2021-05-21 2022-11-24 애니머스큐어 주식회사 이노토디올을 포함하는 근육 질환의 예방 또는 치료용 조성물
WO2025054408A1 (en) * 2023-09-07 2025-03-13 NeuroTherapia, Inc. Methods of treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
WO2019241503A1 (en) 2019-12-19
MX2020013614A (es) 2021-05-27
CN112566641A (zh) 2021-03-26
BR112020025296A2 (pt) 2021-03-09
JP2021527090A (ja) 2021-10-11
US20210252023A1 (en) 2021-08-19
EP3806862A4 (en) 2022-07-06
EP3806862A1 (en) 2021-04-21
US20190381071A1 (en) 2019-12-19
KR20210009422A (ko) 2021-01-26
AU2019285065A1 (en) 2021-01-07
CA3103463A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
SG11202012343TA (en) Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration
IL273959A (en) Methods and preparations for the treatment of rare diseases
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
IL276808A (en) Preparations and methods for the treatment of cancer
IL275626A (en) Preparations and methods for surface treatment
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
IL264176A (en) Methods and preparations for the treatment of cancer
IL285886A (en) Preparations and methods for the treatment of laminopathy
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
SG11202012435UA (en) Compositions and methods for treating cancer
SG11202100675YA (en) Surface treatment compositions and methods
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
SG11202012070YA (en) Methods and compositions for preventing or treating tissue calcification
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
IL290348B1 (en) Compositions and methods for surface treatment
IL285796A (en) Methods and preparations for the treatment of cancer
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
IL276203A (en) Compounds and methods for treating cancer
IL263563A (en) Compounds and methods for treating cancer
IL280868A (en) Preparations and methods for the treatment of acute lung injury
SG11202100417RA (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
GB202214988D0 (en) Compositions and methods for preventing or treating nephrolithiasis